Article
ROS induction as a strategy to target persister cancer cells with low metabolic activity…
medRxiv · 2022 · Eichhoff, O. M.; Stoffel, C. I.; Kaesler, J.; Briker, L.; Turko, P.; Karsai, G.; Zila, N.; Paulitschke, V.; Cheng, P. F.; Leitner, A.; Bileck, A.; Zamboni, N.; Irmisch, A.; Balazs, Z.; Tastanova, A.; Pascoal, S.; Johansen, P.; Wegmann, R.; Mena, J.; Othman, A.; Viswanathan, V.; Wenzina, J.; Aloia, A.; Saltari, A.; Dzung, A.; TuPro Consortium,; Krauthammer, M.; Schreiber, S.; Hornemann, T.; Distel, M.; Snijder, B.; Dummer, R.; Levesque, M.
Key facts
| Title | ROS induction as a strategy to target persister cancer cells with low metabolic activity in NRAS mutated melanoma |
|---|---|
| First author | Eichhoff, O. M.; Stoffel, C. I.; Kaesler, J.; Briker, L.; Turko, P.; Karsai, G.; Zila, N.; Paulitschke, V.; Cheng, P. F.; Leitner, A.; Bileck, A.; Zamboni, N.; Irmisch, A.; Balazs, Z.; Tastanova, A.; Pascoal, S.; Johansen, P.; Wegmann, R.; Mena, J.; Othman, A.; Viswanathan, V.; Wenzina, J.; Aloia, A.; Saltari, A.; Dzung, A.; TuPro Consortium, ; Krauthammer, M.; Schreiber, S.; Hornemann, T.; Distel, M.; Snijder, B.; Dummer, R.; Levesque, M. |
| Journal | medRxiv |
| Published | Oct 27, 2022 |
| DOI | 10.1101/2022.10.19.512839 |
| Devices mentioned | 018257, K040782, K042884, K973350, K990827 |
| Product codes mentioned | IBK, JCJ, JJH, JJQ, JQW, KPA, LXG, MYA, MXZ, NJT, NKF, NPM and 5 more |
At a glance
- 1–9 FDA submissions mentioned
- 10–99 Product codes mentioned
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About Literature
Peer-reviewed and preprint literature indexed by Orca1 and linked to the FDA submissions and product codes each article mentions. Only bibliographic details are shown here.
Source: Publisher and PubMed metadata; device mentions identified by Orca1